Beryl Drugs share price
You have to be logged in to add this to Watchlist.- ₹19.40(-4.90%)May 16, 2025 15:41:41 PM IST
- NSE
- BSE
- Vol : 4.58K (NSE + BSE)Last 20 day avg : 1.62 K
Beryl Drugs is trading -4.90% lower at Rs 19.40 as compared to its last closing price. Beryl Drugs has been trading in the price range of 21.00 & 19.38. Beryl Drugs has given -43.57% in this year & 12.09% in the last 5 days. Beryl Drugs has TTM P/E ratio 227.40 as compared to the sector P/E of 24.25.The company posted a net profit of 0.05 Crores in its last quarter.Listed peers of Beryl Drugs include Decipher Labs (-3.16%), Unjha Formulations (-0.99%), Beryl Drugs (-4.90%).The Mutual Fund holding in Beryl Drugs was at -% in . The MF holding has - from the last quarter. The FII holding in Beryl Drugs was at -% in . The FII holding has - from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on May 16, 2025, 07:46 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/BHigher than historical values1.16The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values128.33Price-to-earnings ratio based on trailing 12-month earnings
- BetaHigh volatility1.61Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.57The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's revenue fell during December quarter by 30.35% from Rs 7.62 crore to Rs 5.31 crore, year-on-year- The company's profit declined by 83.23% year-on-year during the December quarter, dropping from Rs 0.31 crore to Rs 0.05 crore
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
- R1
- 21.82
- R2
- 23.36
- R3
- 25.59
- S1
- 18.05
- S2
- 15.82
- S3
- 14.28
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Decipher Labs | Bearish | 11.34 | -3.16 | 11.46 | - | 0.54 | - | - |
| Unjha Formulations | Bearish | 23.01 | -0.99 | 10.31 | 37.40 | 3.81 | - | - |
| Beryl Drugs | Moderately Bearish | 19.40 | -4.90 | 9.84 | 13.04 | 1.11 | - | 26.94 |
| Cian Healthcare | Moderately Bullish | 3.82 | 1.87 | 9.54 | 37.19 | 0.16 | - | 47.62 |
| Ortin Global | Neutral | 11.84 | 4.87 | 9.63 | - | 3.14 | - | 63.82 |
- Promoter(s) does not have a high stake in the company
- FIIs are not invested in this company
- Mutual Funds are not invested in this company.
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-02-08 | Quarterly Results |
| 2024-11-13 | Quarterly Results |
| 2024-08-09 | Quarterly Results |
| 2024-05-30 | Audited Results |
| 2024-04-20 | Others |
- IndustryBiotechnology & Drugs
- ISININE415H01017
- BSE Code524606
- NSE Code
Beryl Drugs is trading at 19.40 as on Fri May 16 2025 10:11:41. This is -4.90% lower as compared to its previous closing price of 20.40.
The market capitalization of Beryl Drugs is 9.84 Cr as on Fri May 16 2025 10:11:41.
The 52 wk high for Beryl Drugs is 46.00 whereas the 52 wk low is 17.35
Beryl Drugs can be analyzed on the following key metrics -
- TTM P/E: 227.40
- Sector P/E: 24.25
- Dividend Yield: 0.00%
- D/E ratio: -
Beryl Drugs reported a net profit of 0.77 Cr in 2024.